Close
Patheon
    • 15 MARCH 2016

      Flexible Manufacturing Can Help Pharmaceutical Industry Avoid High Costs of Inaccurate Demand Forecasts

      Dateline City:
      DURHAM, N.C.

      Survey about product launch challenges finds instances of demand forecasts off by more than 50 percent, leading to sales losses and reputation damage

      DURHAM, N.C.--(BUSINESS WIRE)--A survey of 50 pharmaceutical industry senior managers found a majority of companies had either overestimated or underestimated demand for new drugs by up to 25 percent, with some reporting instances of forecasts being off by more than 50 percent. The results of the survey – conducted by business intelligence firm ORC International and sponsored by Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries – are published in a white paper, “Pharmaceutical Product Forecasting and Its Impact on Manufacturing.” The white paper includes insights from the 50 industry experts and commentary from Jim Miller, founder and president of PharmSource.

      When a company fails to meet its forecasted demand, the lack of inventory can result in loss of sales, product risk and overworked employees. It is estimated that a delay in launch costs an average of $15 million per drug, per day, and research shows that a blockbuster drug will lose $1 billion in revenue annually until capacity is developed to meet demand. Generally, underestimating resulted from not having enough background data to support forecasting information.

      “Making accurate demand forecasts is extremely challenging for pharmaceutical companies, particularly forecasts for new product launches,” said Michael Lehmann, executive vice president sales and marketing for Patheon. “As a driver of innovation and a transformative force in the industry, Patheon is focused on helping clients find innovative solutions to their challenges.”

      If demand is overestimated, it leads to misappropriated capital, forcing manufacturers to mark down the price of the product, destroy inventory and/or close plants and lay off employees, losing the roughly $500 million it cost to acquire their pharmaceutical plant. Respondents said that they often overestimated demand when there is greater market volatility or when they were overly optimistic in their forecasting.

      These inaccuracies in demand forecasting, combined with increases in complex manufacturing processes, are driving the need for more choices in manufacturing solutions. Pharmaceutical companies have started outsourcing drug production to take advantage of more flexible manufacturing offerings, and to mitigate risks and prevent the reputational damage resulting from inaccurate demand forecasts.

      “It is clear that regardless of company size, product type, or market, the challenge of demand forecasting is a significant one,” said Dana Benini, vice president, ORC International. “Since forecasts by their very definition involve a degree of uncertainty, pharma companies should be talking about how flexible, scalable capacity can accommodate the variability factor, and minimize the impact of inaccurate estimates for a product that does not yet exist.”

      Flexible manufacturing services, like those provided by Patheon, complement the traditional outsourcing service model through adaptable and scalable capacity, and allows clients to increase and decrease capacity as needed. In the face of uncertain forecasts, contract development and manufacturing organizations (CDMOs) like Patheon can offer the facilities, equipment and process technology expertise needed for operations and risk management.

      Patheon commissioned the study to better understand the challenges pharmaceutical companies encounter when implementing demand forecasts for commercial launches. The findings were based on in-depth interviews examining current forecasting processes, key issues that arise from inaccurate forecasting, and how forecasting needs will change in the future.

      Patheon offers a range of flexible manufacturing solutions to address typical manufacturing challenges, and make tomorrow’s medicine’s available today. The company envisions A Healthier World. Delivered. To view the full white paper and ORC research results, visit: http://info.patheon.com/flexiblemanufacturing

      About ORC International

      ORC International is a leader in the art of business intelligence. Our teams are passionate about discovering what engages people around the world. By combining quality data, smart synthesis and best in class digital platforms, we deliver our clients the insight that powers growth and drives the future of their business. For more information, please visit www.ORCInternational.com.

      About Patheon

      Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com

      Language:
      English
      Contact:

      Patheon
      Mari Mansfield, Senior Director, External Communications
      919-226-3137, Mari.Mansfield@Patheon.com
      media@patheon.com

      @patheon

      Patheon publishes independent research paper on drug manufacturing forecasting inaccuracies.

      ... Read more
    • 14 MARCH 2016

      Patheon Signs Flexible Manufacturing Agreement with Amgen

      Dateline City:
      DURHAM, N.C.

      DURHAM, N.C.--(BUSINESS WIRE)--Patheon, the leading global provider of pharmaceutical development and manufacturing services, announced today that it has signed a manufacturing agreement with Amgen, one of the world’s leading biotechnology companies, headquartered in Thousand Oaks, CA.

      Amgen has selected Patheon to provide flexible manufacturing solutions to meet the growing demand for their innovative human therapeutics. “As we launch new products and expand into more countries, it is critical to have the capacity to respond to increases in demand for our medicines,” said Rayne Waller, vice president, global supply chain at Amgen. “Manufacturing remains a core competency and a competitive advantage for Amgen and we are committed to supplying every patient, every time. This arrangement with Patheon supplements our own manufacturing network and provides us flexibility to ensure supply.”

      The rapidly changing biopharmaceutical marketplace presents tremendous challenges for biotechnology companies when it comes to demand forecasting. To address this, Patheon has developed unique solutions and business models providing flexible manufacturing options for clients to address the complex client needs in a changing landscape.

      “We believe the departure from the “build or buy” paradigm represents a superior value for our clients,” said Michael Lehmann, executive vice president, global sales and marketing for Patheon. “These flexible capacity solutions require a strategic and collaborative approach – different from the traditional “price per batch” concept. This agreement with Amgen is representative of the changing dialogue in the pharmaceutical services industry.”

      Patheon provides world class process development and cGMP manufacturing services for both drug substance and drug product, from pre-clinical to commercial supply, to its global client base.

      About Patheon

      Patheon is a leading global provider of pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com.

      Language:
      English
      Contact:

      Patheon
      Mari Mansfield, Senior Director, External Communications
      919-226 -3137; Mari.Mansfield@Patheon.com
      media@patheon.com

      @patheon
      ... Read more
    • 22 FEBRUARY 2016

      Patheon Selected by Grünenthal to Develop Drugs Using INTAC® Abuse Deterrent Formulations Technology

      Dateline City:
      DURHAM, N.C.

      DURHAM, N.C.--(BUSINESS WIRE)--Patheon, the leading global provider of pharmaceutical development and manufacturing services today announced it has signed a strategic agreement with Grünenthal, an independent, family-owned, international research-based pharmaceutical group headquartered in Aachen, Germany, to serve as its preferred development partner for its products made using Grünenthal’s innovative abuse deterrent formulation technology INTAC®.

      Patheon was selected to assist with the development of advanced INTAC® based products including single-entity and fixed-dose combination solid oral dosage forms with immediate and modified release properties. INTAC® is Grünenthal’s proprietary technology designed to reduce the potential for abuse of controlled substances.

      As part of the agreement, Grünenthal has agreed to install specialized equipment in Patheon’s Cincinnati manufacturing site. Through their partnership, Grünenthal and Patheon will offer new solutions to the broader pharmaceutical industry. This concept of locating equipment in a Patheon facility – “condo model” – allows clients to benefit from Patheon’s process, people and infrastructure to simplify manufacturing.

      “This agreement is a tangible example of the deeper, collaborative relationships we are pursuing and winning with clients,” said Mike Lehmann, executive vice president, global sales and marketing, Patheon. “Over the past several years we have built a business to meet the needs of a breadth of clients – from emerging pharma companies to large multinationals.”

      This collaboration brings together Grünenthal’s innovative approach to research and development and the specialized technical manufacturing capabilities of Patheon to bring novel therapies to the marketplace for the patients who need them.

      Dr. Klaus-Dieter Langner, chief scientific officer Grünenthal Group said, “It is recognized in the healthcare industry that prescription drug abuse is an issue of growing concern in the United States. Typically it is opioids, CNS depressants and stimulants that are the three most established drug classes that are abused. Novel formulation technologies will help reduce that abuse potential.”

      About INTAC®

      With its innovative abuse-deterrent formulation technology platform, INTAC®, Grünenthal is leading the field with already several FDA-approved opioid products utilizing this unique technology which confers outstanding crush resistance of drug matrix and raises hurdles against prescription drug abuse. Grünenthal considers INTAC® to be a leading technology for tamper-resistant opioid products.

      Grünenthal has expanded the INTAC® platform beyond extended release formulations to immediate release as well as modified release dosage forms of single-entity and fixed-dose combination products. This allows Grünenthal to offer this technology now for a broader variety of drugs and abuse deterrent applications. More information: www.intac.grunenthal.com

      About Grünenthal

      The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Grünenthal is an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.

      Altogether, the Grünenthal Group is with affiliates present in 32 countries in Europe, Latin America and the US. Grünenthal products are sold in more than 155 countries and approx. 5,300 employees are working for the Grünenthal Group worldwide. In 2014, Grünenthal achieved revenues of € 1.154 bn. More information: www.grunenthal.com

      About Patheon

      Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com

      Language:
      English
      Contact:

      Grünenthal GmbH
      Steffen Fritzsche, +49241 569 1335
      Senior Director Corporate Communications
      Steffen.Fritzsche@grunenthal.com
      Fax: +49 241 569 51335
      or
      Patheon
      Mari Mansfield, +1-919-226-3137
      Senior Director, Corporate Communications
      Mari.Mansfield@Patheon.com
      media@patheon.com

      @patheon
      ... Read more
    • 17 FEBRUARY 2016

      Patheon Customers Save Up to Six Months of Development Time with New Filling Technology

      Dateline City:
      DURHAM, N.C.

      Patheon Introduces Xcelodose® Automated Encapsulator Technology at Milton Park, U.K. Facility

      Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has added a new filling technology that significantly reduces the time needed for formulation development and stability testing at its Milton Park, U.K., facility. The Xcelodose ® 600 S Automated Encapsulator, supports early phase development for oral dose products.

      This technology adds to the site’s breadth of services, from early development to life cycle management of both small and large molecules, as well as enhances Patheon’s Quick to Clinic™ capabilities . The Xcelodose ® 600 S, allows for manufacturing active pharmaceutical ingredients (API), in capsule form, for Phase I through pilot-scale Phase II clinical trials. The technology fills API directly into capsules, with no need for excipients, and can save up to six months of development time by reducing the need for formulation development and stability testing. The Xcelodose ® technology offers precision at filling speeds of more than 600 capsules per hour and ten times faster than manual filling methods.

      “With this new technology, we can bring medications to trial more quickly for our customers,” said Dr. Jon Sutch, Ph.D., manager of formulation at Milton Park. “Patheon is a proven leader in pharmaceutical development services (PDS), using innovative, cutting-edge technologies, like the Xcelodose®, to provide customers with unsurpassed quality, solutions and value.”

      Patheon’s Milton Park facility focuses on the development and formulation of semi-solid, oral liquid and solid dosage forms at the earliest development phases, and aims to bring projects to clinical trials as quickly as possible. PDS operations provide integrated services ranging from pre-formulation, formulation, analytical development, clinical trial material manufacturing and packaging, and scale-up, including biopharmaceuticals.

      About Patheon

      Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com .

      Language:
      English
      Contact:

      Patheon Media Relations
      919-210-0986
      tyler.gronbach@patheon.com
      media@patheon.com

      ... Read more
    • 8 FEBRUARY 2016

      Patheon Appoints Andrew G. Long as Senior Vice President and Global Business Controller

      Dateline City:
      DURHAM, N.C.

      DURHAM, N.C.--(BUSINESS WIRE)--Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, has hired Andrew G. Long as senior vice president and global business controller. Long will report to Stuart Grant, chief financial officer for Patheon, and will be based at the company’s headquarters in Durham, N.C.

      Long will focus on Patheon’s financial planning and performance management tools and processes, in support of the company’s position as a category leader in the pharma services industry.

      He brings more than 25 years of experience to Patheon. He most recently served as vice president, global finance of the Fisher Scientific Group for Thermo Fisher Scientific, a biotechnology product development company, where he was responsible for global financial planning and analysis, controllership, mergers and acquisitions and strategic planning.

      “Andy is a great addition to our organization, said Grant. “He is a seasoned professional with vast experience in all aspects of finance. We will benefit from his experience as we advance our business strategy.”

      Prior to joining Thermo Fisher, Long was vice president, worldwide finance and supply chain management at Cambrex Corporation, responsible for global financial planning, reporting and analysis for a division with 14 manufacturing and distribution sites across 10 countries. Previously, Long served in a number of roles of increasing responsibility for companies including Eaton Corporation, Emerson Electric and Abbott Laboratories.

      “I am very pleased to join Patheon,” said Long. “The company is widely recognized as a market leader with a solid growth profile.”

      Long holds a Bachelor of Science from Indiana University and a Master of Business Administration from the Kellogg Graduate School of Business, Northwestern University.

      About Patheon

      Patheon is a leading global provider of pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com

      Language:
      English
      Contact:

      Patheon
      Mari Mansfield, 919-226-3137
      Mari.Mansfield@Patheon.com
      media@patheon.com

      @patheon

      Andrew Long named SVP and global business controller for Patheon

      ... Read more
    • 2 FEBRUARY 2016

      Patheon Appoints Leader for Biologics

      Dateline City:
      DURHAM, N.C.

      Industry Veteran, Steve Lam, to Direct Rapidly Expanding Business

      DURHAM, N.C.--(BUSINESS WIRE)--Patheon today announced the appointment of Steve Lam as senior vice president of the company’s biologics business. Lam will report to Lukas Utiger, president of the company’s Drug Substance Services (DSS) segment, effective immediately. Biologics is a fast-growing area of the industry, which requires experience and expertise because of their complexity.

      For the past 18 years, Lam has served as vice president of operations for Amgen, one of the world's leading independent biotechnology companies. He led a company-wide transformation initiative driving robust quality management processes and operational excellence. He brings to Patheon more than 25 years of leadership experience in biopharmaceutical operations with a focus on manufacturing and commercializing human therapeutics. He has specific expertise in protein manufacturing, cGMP compliance, quality systems and technology transfer.

      “Our biologics business is an area with tremendous growth potential for Patheon,” said Utiger. “With Steve’s experience and his broad client perspective, he will energize our efforts and support our biopharmaceutical clients who are looking for a knowledgeable partner with scale and expertise to meet their needs. He will help us to continue to pursue strategies that capitalize on this expanding area of our business.”

      Lam’s experience includes responsibility for lean manufacturing transformation and driving efforts toward greater efficiency. His efforts to improve manufacturing strategy, reduce risk and enhance product quality resulted in increased revenue while providing Amgen with new capabilities.

      Lam earned a Bachelor of Arts degree in chemistry from Knox College in Galesburg, Illinois. He also attended the Executive Development Program at Northwestern University in Evanston, IL. He will be based at Patheon’s offices in Boston.

      About Patheon

      Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com

      Language:
      English
      Contact:

      Patheon
      Mari Mansfield, 919-226-3137
      Mari.Mansfield@Patheon.com
      media@patheon.com

      @Patheon

      Steve Lam, an industry veteran, will head Patheon's biologics business

      ... Read more
    • 11 JANUARY 2016

      Life Sciences Executive to Join Patheon

      Dateline City:
      DURHAM, N.C.

      Gilles Cottier to lead the company’s PDS business

      DURHAM, N.C.--(BUSINESS WIRE)--Patheon announced today the appointment of Gilles Cottier as president of the company’s pharmaceutical development services (PDS) division effective immediately. He will serve as a member of Patheon’s executive committee and will report to Patheon CEO James Mullen.

      The appointment of Cottier is part of a larger realignment effort by the company to create three distinct business segments – drug product services (DPS), drug substance services (DSS) and PDS. This will help the company forge deeper relationships with clients and employ new business models to help clients simplify their supply chain management activities. Patheon’s three business segments are led by key executives: Franco Negron for DPS, Lukas Utiger for DSS and now Cottier for PDS.

      Cottier will assume the responsibilities for the PDS business from Michael Lehmann who was leading both Global PDS and Global Sales and Marketing. Lehmann will now focus on the Sales and Marketing function to support the expanding number of new business opportunities and increasing complexity of client relationships.

      “Gilles brings a wealth of relevant experience in the life science and technology sector, including the manufacture of chemical and biochemical compounds, contract manufacturing and commercial services,” said Mullen. “I’d also like to thank Mike Lehmann for his outstanding leadership of the PDS business during his tenure. We established ourselves as the global market leader of PDS services.”

      Cottier joins Patheon from Sigma-Aldrich Corporation where he was executive vice president and president of the Sigma-Aldrich Fine Chemicals (SAFC) Commercial Unit overseeing the contract manufacturing and the commercial services business unit which achieved more than $700 million in sales in 2014.

      Cottier held numerous positions of increasing responsibility at Sigma-Aldrich during his more than 25 years with the company. He earned a master’s degree in organic chemistry from the Ecole Supérieure de Chimie Industrielle de Lyon, France and advanced management program from the Harvard Business School in Boston, MA.

      About Patheon

      Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com

      Language:
      English
      Contact:

      Patheon
      Mari Mansfield, 919-226-3137
      Mari.Mansfield@Patheon.com
      media@patheon.com

      ... Read more
    • 22 OCTOBER 2015

      Patheon to Highlight Solubility Solutions and Patheon OneSource™ at 2015 AAPS Annual Meeting and Exposition

      Dateline City:
      DURHAM, N.C.

      Company to present 17 posters on a range of topics from validation of stability to process optimization

      Experts from Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will present on a breadth of industry topics at the 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, being held Oct. 25-29 in Orlando, Fla.

      Marshall Crew, vice president of global PDS scientific excellence, will deliver a presentation titled, “Improving Poor Solubility and Bioavailability with Solid Dispersions: Why, When and How?” on Sunday, October 25 from 9:05-10:00 a.m. in room W205C. In addition, Patheon will host daily in-booth sessions discussing Patheon OneSource™, continuous manufacturing and formulation computer modelling.

      Several scientific experts from Patheon will also present 17 posters on a range of pharmaceutical development and manufacturing topics including, solubilization using amorphous dispersions and hard shell gelatin capsules, stability studies, process optimization, analytical method development and lyophilization. A complete list of all Patheon poster presentations can be viewed by clicking here .

      Patheon executives as well as technical and scientific experts attending AAPS will be available to discuss the company’s full services and capabilities. Representatives can be found at booth #405 for the duration of the conference.

      With an expected attendance of almost 7,500 and representation from dozens of countries, the AAPS Annual Meeting and Exposition showcases late-breaking research, validates scientific methodology and reveals the latest technology, services and supplies. Speakers include scientists from the Food and Drug Administration, National Institute of Health, leading pharmaceutical companies and academia.

      For more information on upcoming events, visit http://www.patheon.com/Knowledge-Library/Events.aspx .

      About Patheon

      Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com.

      Language:
      English
      Contact:

      Patheon
      Mari Mansfield, 919-226-3137
      Mari.Mansfield@Patheon.com
      media@patheon.com

      ... Read more
    • 5 OCTOBER 2015

      Patheon to Highlight Flexible Capacity Solutions and Solubilization at CPhI/ICSE Worldwide 2015

      Dateline City:
      DURHAM, N.C.

      Patheon’s Marshall Crew, Ph.D., and Joe Principe to present in the Speaker’s Corner on Oct. 14

      Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will be on site at the 26th Annual CPhI/ICSE Worldwide conference from , Oct. 13 - Oct. 15, in Madrid.

      Two noted Patheon experts will present at the Speaker’s Corner on Wednesday, Oct. 14.

      At noon, Marshall Crew, Ph.D. and vice president, global PDS scientific excellence, will discuss how to optimize solubilization strategies and unlock the potential of promising drugs in his presentation, “The Story of Solubilization: New Data and Insights on the Past and What Lies Ahead.” Low solubility is a growing issue in the successful development of pharmaceutical products, and solubility outcomes can be unpredictable. Crew will explore the scientific expertise that is required to ensure success for these increasingly complex formulations, and the multiple technologies available to address solubility.

      In addition, Joe Principe, vice president of global alliance accounts, will present “Mitigating Uncertainty in Demand Forecasting with Flexible Capacity Solutions” at 2:30 p.m. Pharmaceutical companies develop forecasts to estimate future needs, but predicting performance in a market filled with competing products that do not yet exist is problematic. Principe will discuss several ways to provide cost-effective flexible manufacturing capacity.

      Patheon executives, technical and scientific experts attending CPhI/ICSE Worldwide will be available to discuss the company’s full services and capabilities. Representatives can be found at booth #3F10 for the duration of the conference. To schedule a meeting in advance, please email media@patheon.com.

      For more information on upcoming events, visit http://www.patheon.com/Knowledge-Library/Events.aspx.

      About Patheon

      Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com

      Language:
      English
      Contact:

      Patheon
      Mari Mansfield, 919-226-3137
      Mari.Mansfield@Patheon.com
      media@patheon.com

      ... Read more
    • 28 SEPTEMBER 2015

      Patheon Unveils New Brand and Identity

      Dateline City:
      DURHAM, N.C.

      “A Healthier World. Delivered.™” Reflects Company’s Focus on Helping Customers Deliver Life-changing Medications

      Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, today unveiled its new brand identity, reflecting the company’s leadership position in the pharmaceutical services industry, and the difference it makes in the lives of patients.

      The new brand positioning centers around an updated brand promise based on the fundamental belief; the world would be a healthier place if tomorrow’s medicines were made available today. The branding elements include a creative visual system, an updated logo and a new company tag line that together represent how the company is differentiated, compelling and best-equipped to help address client challenges.

      A Healthier World. Delivered.™

      The new tag line promises a healthier world, and is meant to reflect the company’s commitment to working closely with clients to help them find solutions to some of their greatest formulation development and manufacturing challenges.

      “People around the world depend on life-changing medications from pharmaceutical companies and Patheon is delivering those medications every day through its dedicated workforce,” said Chris Tama, senior vice president of marketing. “Our new brand platform promotes our leadership position, the work our employees perform around the world and the fact that we are uniquely positioned to provide end-to-end pharmaceutical development and manufacturing services under a single, master brand.”

      The Maker’s Hand

      The visual of a working hand represents the Patheon employees who make and deliver life-changing medicines to patients waiting for them. The image captures trust and partnership, and insights gained through years of experience and the highest level of expertise to efficiently deliver better performance, care and quality.

      A completely redesigned website revealing the modern new design has also been launched as part of the rebranding exercise, with the new visuals clearly and effectively communicating the company’s differentiators and value proposition. The promotion will be part of a global effort to help current and prospective clients better understand how Patheon can help address the most complex development and manufacturing needs. The new brand will be applied to all promotional materials and communication channels, and rolled out behind a global promotional campaign in publications and trade journals, along with digital brochures and sales tools. The brand was first unveiled to Patheon’s most valuable asset – its employees – who are represented by the maker’s hand.

      About Patheon

      Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com

      Language:
      English
      Contact:

      Tyler Gronbach
      Tel: +1 (919) 210-0986
      Email: tyler.gronbach@patheon.com
      media@patheon.com

      ... Read more
    • 22 JULY 2015

      Ardian Acquires Exclusive Synthesis (ES) and Maleic Anhydride Intermediates & Specialties (IM) Business From DPx Holdings B.V.

      Dateline City:
      DURHAM, N.C.

      Ardian, together with current management, to acquire agrochemicals (ES) and fine chemicals (IM) business activities of DPx Holdings B.V. to gain full independence, expand product portfolio and further international growth

      Ardian, the independent private investment company, today announces the acquisition of the Exclusive Synthesis (ES) and Maleic Anhydride Intermediates & Specialties (IM) business activities, based in Linz, Austria, of DPx Holdings B.V. The parties have agreed not to disclose details of the transaction. The completion of the transaction is still subject to approval by the antitrust authorities.

      ES and IM are leading European chemical manufacturers in their respective market segments and have a 75-year tradition of translating the latest research results into scalable intermediates and end products. In the context of custom synthesis, ES develops and produces chemical intermediate products for agriculture and other industries. IM produces maleic anhydride, a large number of intermediates, derivatives and esters. With a longstanding and broad customer base, ES and IM generated combined sales of around €200 million for the 2014 financial year and have around 390 employees.

      With the support of Ardian, the management of ES and IM plans to significantly strengthen its market position. Ardian’s Mid Cap Buyout Team has extensive experience in the chemicals sector from previous and current investments in companies such as CABB, Novacap, Italmatch and Eliokem. This investment will focus on expanding the product portfolio through organic growth – building on the strength of existing and new customer relations – as well as through targeted strategic acquisitions. The company will also seek to realize its international growth potential by further expanding into new markets.

      Wolfgang Hillisch, current Managing Director of ES and IM and designated CEO, said: “With numerous investments in the chemicals industry, the Ardian team has demonstrated its familiarity with this area. We are pleased to have found an experienced and dependable partner in Ardian, as they will support the systematic development of our activities and the implementation of our growth plans.”

      Wolfgang Pietzsch, Managing Director in the German Mid Cap Buyout Team at Ardian, added: “ES and IM already hold a leading position in the growing markets for fine and agricultural chemicals. Together with the experienced and strong management team, we foresee great potential for the business to develop as an independent group through internationalization and expansion of the product portfolio, targeted acquisitions and by providing crucial momentum for the further growth of the company.”

      “We are pleased to have identified a buyer for the ES and IM operations of our business in Linz that is committed to growing the operations,” said Lukas Utiger, president, DPx Fine Chemicals which is owned by DPx Holdings. “We are confident that with the support of Ardian, ES and IM will continue to provide first-class service and support to its customers while we focus our energies and efforts on growing our end-to-end pharmaceutical development and manufacturing services.”

      ADVISORS TO THE TRANSACTION

      Ardian Team:

      Legal: Willkie Farr & Gallagher, Binder Groesswang

      Commercial: Arthur D. Little

      Financial: Ernst & Young

      Tax: Ernst & Young

      Carve out: Ernst & Young

      Insurance: Willis

      Environmental: Golder Associates

      Operational: ChemAdvice

      DPx Holding B.V.:

      M&A: Rothschild

      Legal: Schoenherr

      Hill Smith King & Wood

      Financial: Deloitte

      Ardian

      Charles Barker

      KORNELIA SPODZIEJA

      kornelia.spodzieja@charlesbarker.de

      Phone: +49 69 79409040

      Mobile: +49 172 6227007

      TOBIAS EBERLE

      tobias.eberle@charlesbarker.de

      Phone: +49 69 79409024

      Mobile: +49 173 5204436

      DPx Holding B.V.

      Patheon Media Relations

      tyler.gronbach@patheon.com or media@patheon.com

      Phone: +1 (919) 210-0986

      ABOUT ARDIAN

      Ardian, founded in 1996 and led by Dominique Senequier, is an investment company with assets of US$50bn managed or advised in Europe, North America and Asia. The company keeps entrepreneurship at its heart and delivers investment performance to its global investors while fuelling growth in economies across the world. Ardian’s investment process embodies three values: excellence, loyalty and entrepreneurship. Ardian is majority owned by its employees.

      Ardian maintains a truly global network, with more than 350 employees working through ten offices in Paris, London, New York, Beijing, Frankfurt, Jersey, Luxembourg, Milan, Singapore and Zurich. The company offers its 355 investors a diversified choice of funds covering the full range of asset classes, including Direct Funds (Mid Cap Buyout, Infrastructure, Expansion, Ardian Growth, Co-Investment), Private Debt and Fund of Funds (primary, early secondary and secondary).

      www.ardian.com

      ABOUT DPx Holdings B.V.

      DPx Holdings B.V. is parent company of the Patheon, DPx Fine Chemicals and Banner Life Sciences businesses. DPx Holdings has a footprint of more than 20 locations across North America, Europe and Australia. For more information please go to www.dpxholdings.com.

      Language:
      English
      ... Read more
    • 22 JULY 2015

      LIVIA Group acquires Patheon Facility in Capua, Italy

      Dateline City:
      DURHAM, N.C.

      LIVIA Group, a German-based industrial holding, has entered into an agreement to acquire the Capua manufacturing facility and associated employees from Patheon, a leading global provider of outsourced contract development and manufacturing (CDMO) services for the pharma and biopharma industries. Capua, one of the world’s largest independent microbial fermentation-based manufacturing facilities with 1,400m³ fermentor capacity, represents an exceptional investment opportunity for LIVIA in the highly attractive market of enzymes and small molecules.

      “LIVIA Group is enthusiastic about working with Capua to build on their existing strong market position, through a focus on product development, a revitalized sales function and improved production efficiency,” said Prof Dr Dr Peter Löw, Chief Executive and founder of LIVIA Group. “We are very pleased to be invested in the business and look forward to supporting its future growth.”

      Capua delivers enzymes, therapeutic proteins and high-value small molecules for applications in food, feed, pharma, agrochemical and fine chemical industry. The facility is both FDA and EMEA (Pharma cGMPs) approved as well as ISO 14001 certified and serves customers in more than 60 countries. In addition to its regular production, Capua offers pilot plant capabilities for customized product development, process scale-up and validation.

      “We are very pleased to find a buyer for the Capua facility that is focused on servicing existing customers and adding new ones,” said Lukas Utiger, president drug substance services at Patheon. “Selling the Capua site is part of Patheon’s efforts to focus its core business strategy as a leading global provider of outsourced, end-to-end pharmaceutical development and manufacturing services. We elected to sell the operations to LIVIA Group, who is very focused on growing the operations and continuing to provide a positive work environment for employees.”

      About LIVIA Group

      With funds under management amounting to more than EUR 500m, LIVIA Group is an independent industrial holding company and the investment firm of Prof Dr Dr Peter Löw, concentrating on a diverse spectrum of assets ranging from corporate, real estate, agricultural, emerging markets and opportunistic investments.

      LIVIA Corporate Investments is specializing in acquiring European corporate spin-offs / carve-outs and midsized companies with i) development potential through operational engagement, ii) below industry average profitability, iii) restructuring or transformation needs, or iv) synergies with existing platform-investments and a revenue size between EUR 20m to EUR 1.5bn. With over 220 successfully executed transactions, LIVIA’s management has become a trusted partner among international corporates.

      About Patheon

      Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle.

      Language:
      English
      Contact:

      Stephan Herre, stephan.herre@livia-group.com, +49 89 5527580
      Tyler Gronbach, media@patheon.com, +1 919 226 3165

      ... Read more
    • 15 JULY 2015

      Patheon Announces Biologics Deal with Inhibrx

      Dateline City:
      DURHAM, N.C.

      Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, has entered into a development contract with Inhibrx, abiologic immunotherapeutic company focused on high, unmet medical needs in oncology, infectious disease and inflammatory conditions.

      As part of the agreement, Patheon will develop production processes at its Princeton, N.J., facility and will manufacture products at its Brisbane, Australia, location in support of a pipeline of future programs with Inhibrx. The initial development work will focus on establishing platform processes for Inhibrx’s cell lines.

      “Early stage biotech companies are the pipeline for our industry and we are excited to work with Inhibrx on their development projects, supporting their strategy through our fast-tracked timelines, robust platforms and technology transfer methodologies,” said Manja Bouman, president, Patheon biologics. “By working with our Brisbane facility, Inhibrx is eligible for a cash return under the Australian R&D Tax Incentive, a program in which Patheon’s customers may receive attractive incentives, helping to ensure much-needed biopharmaceutical solutions are delivered to the healthcare sector.”

      “Patheon Biologics has the track record, customer service and scale to support our extensive pipeline of biologic therapeutics. We look forward to working together to rapidly bring innovative therapeutics to patients in need,” said Mark Lappe, CEO of Inhibrx.

      The announcement was made during a reception hosted by Patheon and opened by the Premier of Queensland, Australia, Annastacia Palaszczuk, on June 14, ahead of the BIO International Conference in Philadelphia.

      “The developments send a clear message that Queensland is a great place to invest. We have excellent infrastructure, talented scientists, the rigorous research and the drive to produce outcomes through partnerships,” said Ms. Palaszczuk. “You also have a government in Queensland willing to work with business and the research community to grow a strong life sciences industry in the state, to create jobs for Queenslanders and diversify the economy.”

      Patheon’s state of the art Brisbane facility plays a key role in the company’s integrated biologics business and global footprint, focused on clinical and commercial drug substance production for biotech companies. Patheon also has biologics sites in St. Louis, Mo., Princeton, N.J., and Groningen, the Netherlands.

      Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com.

      Language:
      English
      Contact:

      Patheon Media Relations
      919-210-0986
      tyler.gronbach@patheon.com or media@patheon.com

      ... Read more
    • 11 JULY 2015

      Patheon to Exhibit Biologics Services and Expertise at 2015 BIO International Convention

      Dateline City:
      DURHAM, N.C.

      Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will showcase ways to accelerate biologic process development and funding options for biopharmaceutical programs at the BIO International Convention in Philadelphia, from Tuesday, June 16, to Wednesday, June 17.

      Two of Patheon’s biologics rapid development and scale-up experts, Matt Caple, scientific director, cell culture development, and Tertia Dex, director, business development, will offer exclusive scientific information sessions at booth #1374. Caple will discuss ways to reduce biologic process development timelines, while Dex will speak on non-dilutive funding for biopharmaceutical programs and how companies can receive up to 45 percent cash back through the Australian research and development tax incentive.

      Sessions will take place between 9:30 a.m. and 11:30 a.m. on Tuesday, and 2:30 p.m. and 3:30 p.m. on Wednesday. To view specific session times and schedule a meeting with Dex or Caple, visit http://info.patheon.com/2015-BIO-International.

      Patheon will also host a reception for the Premier and other government officials from Queensland, Australia, on June 14, prior to the convention’s kick off. Patheon’s facility in Brisbane, Australia, was awarded the 2014 International Society of Pharmaceutical Engineering (ISPE) Facility of the Year Award for process innovation, and supports the company’s biologics business and global footprint.

      About Patheon

      Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com.

      Language:
      English
      Contact:

      Patheon Media Relations
      919-210-0986
      tyler.gronbach@patheon.com or media@patheon.com

      ... Read more
    • 8 JUNE 2015

      Patheon Files Registration For Initial Public Offering

      Dateline City:
      DURHAM, N.C.

      Patheon, a leading global provider of outsourced pharmaceutical development and manufacturing services through its end-to-end integrated service offering, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

      J.P. Morgan, Morgan Stanley, Jefferies and UBS will act as joint book-running managers for the proposed offering. The proposed offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, Attention: Prospectus Department c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717 or via telephone: +1 (866) 803-9204 or, from Morgan Stanley & Co. LLC, Attention: Prospectus Department., 180 Varick Street, 2nd Floor, New York, NY 10014, via telephone: +1 (866) 718-1649 or by email:prospectus@morganstanley.com.

      The registration statement on Form S-1 filed with the SEC has not yet become effective and the shares to be registered may not be sold nor may offers to buy be accepted prior to the time when the registration statement becomes effective. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov.

      This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

      About Patheon

      Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. The company is owned by JLL Partners and Royal DSM.

      Language:
      English
      Contact:

      Patheon
      Tyler Gronbach, +1-919-210-0986
      tyler.gronbach@patheon.com or media@patheon.com

      ... Read more
    • 27 MAY 2015

      Patheon Scientist Dr. Marshall Crew Named to Medicine Maker Power List 2015

      Dateline City:
      DURHAM, N.C.

      Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors , today announced that Dr. Marshall Crew, vice president, global PDS scientific excellence, has been named one of the top 100 most influential people in drug development and manufacture by the publication The Medicine Maker.

      Dr. Crew, an elite scientist and expert in low-solubility drug formulation, was previously CEO and founder of Agere Pharmaceuticals, a CDMO specializing in oral bioavailability of insoluble molecules that was recently acquired by Patheon. Dr. Crew’s career has been devoted to improving the delivery of poorly soluble drugs through innovation and technology. He has close to 30 patents and patent applications filed under his name.

      “It is an honor to be included among such an accomplished group,” Dr. Crew said. “As a community, I’m optimistic that we will see many more advances realized by these accomplished scientists, engineers and healthcare professionals, who are working relentlessly toward driving positive change for the critical needs of patients.”

      UK-based The Medicine Maker is a monthly publication with a focus on clinical, regulatory, development and manufacturing fields for biopharmaceuticals. The publication’s readers nominate individuals to the annual Power List, which is selected and ranked by an independent jury.

      About Patheon

      Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com.

      Language:
      English
      Contact:

      Patheon Media Relations
      +1-919-210-0986
      tyler.gronbach@patheon.com or media@patheon.com

      ... Read more
    • 13 MAY 2015

      Patheon to Sponsor Webinar on Assessing Stability for Shipment of API and Drug Products

      Dateline City:
      DURHAM, N.C.

      Analytical development experts will address questions about regulatory requirements, and stability and shipping studies in a complimentary webinar this month sponsored by Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries. Hosted by Pharmaceutical Technology , a comprehensive information source for professionals in the global pharmaceutical manufacturing drug development community, the webinar “Stability Assessment for Shipment of API and Drug Products,” will provide guidance on the evaluation of APIs and drug products shipment, and will be held Thursday, May 21, from 11 a.m. to 12 p.m. EDT.

      Patheon recently announced that it is investing more than $3 million to expand its Greenville, N.C. site’s stability testing capabilities. This will allow the facility to offer more than 30,000 cubic feet of state-of-the-art stability storage, and the capabilities to support the largest, most complex projects on small molecule APIs, large molecule biologics and drug substances, solid oral dose drugs, sterile liquid or lyophilized drugs, controlled substances and highly potent compounds.

      Webinar participants will hear about the evolving regulatory expectations for stability studies, review challenges in global studies and learn how to improve strategies for biological stability studies. The presenters, Geoff Carr, Ph.D., director, analytical development at Patheon, and Vladimir Golynskiy, Ph.D., senior manager, analytical development at Patheon, will discuss the approaches to assessing stability of biologic APIs and small-molecule drug products throughout expected product shipment. The live webcast will be moderated by Rita Peters, editorial director at Pharmaceutical Technology.

      For more information and to register for free, please visit www.pharmtech.com/pt/stability.

      About Patheon®

      Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com .

      Language:
      English
      Contact:

      Patheon Media Relations
      +1-919-210-0986
      tyler.gronbach@patheon.com or media@patheon.com

      ... Read more
    • 12 MAY 2015

      Patheon Expands Stability Testing Capabilities in Greenville, NC

      Dateline City:
      DURHAM, N.C.

      Company Invests $3 million in Equipment and Talent in its Centralized Stability Testing Lab

      Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, is investing more than $3 million to expand its Greenville, N.C. site’s stability testing capabilities. The expansion includes the addition of the most advanced automated systems and the assembly of a highly experienced scientific team to enhance its centralized stability lab offerings.

      Since 2011, more than 1,000 stability studies with 110 different products have been initiated at Patheon’s stability lab in Greenville. With this expansion, the facility now offers more than 30,000 cubic feet of state-of-the-art stability storage, and the capabilities to support the largest, most complex projects on small molecule APIs, large molecule biologics and drug substances, solid oral dose drugs, sterile liquid or lyophilized drugs, controlled substances and highly potent compounds.

      “Our complete suite of advanced analytical tools dedicated to stability testing delivers accelerated results for customers’ late-stage development and commercial projects, providing high-quality data in 30 days or less,” said Bill Weiser, Ph.D., executive director and global head of analytical sciences. “An additional benefit is that the stability lab’s high-tech chromatography system will be fully integrated with the data reporting system which allows customers to access their data anytime, anywhere allowing for quicker access to submission-ready reports.”

      Patheon is a recognized leader in quality, and the investment in its Greenville facility demonstrates the company’s commitment to continued growth and customer needs. Companies facing costly upgrades to their in-house stability capabilities will benefit greatly from the use of Patheon’s efficient and cost-effective centralized stability services.

      About Patheon

      Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com.

      Language:
      English
      Contact:

      Patheon Media Relations
      +1-919-210-0986
      tyler.gronbach@patheon.com or media@patheon.com

      ... Read more
    • 29 APRIL 2015

      JLL/Delta Dutch Pledgeco B.V. Announces Pricing of its Private Placement of $550 Million 8.75% / 9.50% Senior PIK Toggle Notes due 2020

      Dateline City:
      DURHAM, N.C.

      JLL/Delta Dutch Pledgeco B.V. (the “Company”), the parent company of DPx Holdings B.V., announced today the pricing of the previously announced private offering of $550 million aggregate principal amount of its 8.75% / 9.50% Senior PIK Toggle Notes due 2020 (the “Notes”). The total size of the offering of the Notes has been increased from $500 million to $550 million. The Company intends to use the net proceeds from the offering of the Notes to pay a dividend or other distribution to its parent company and certain related transaction fees and expenses related to the offering.

      The offering of the Notes will be made in a private transaction in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), in the United States only to investors who are “qualified institutional buyers,” as that term is defined in Rule 144A under the Securities Act, or outside the United States pursuant to Regulation S under the Securities Act. The Notes have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.

      This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any of the Notes in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

      Cautionary Statement

      No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

      Forward-Looking Statements

      This press release contains forward-looking statements. These forward-looking statements reflect management’s expectations regarding our future growth, results of operations, operational and financial performance and business prospects and opportunities. All statements, other than statements of historical fact, are forward-looking statements. You can identify such statements because they contain words such as “plans,” “expects” or “does not expect,” “budget,” “forecasts,” “anticipates” or “does not anticipate,” “believes,” “intends” and similar expressions or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved. Although the forward-looking statements contained in this press release reflect management’s current beliefs based upon information currently available to management and upon assumptions which management believes to be reasonable, actual results may differ materially from those stated in or implied by these forward-looking statements.

      About DPx Holdings B.V.

      JLL/Delta Dutch Pledgeco B.V. is the parent company of DPx Holdings B.V., which is the parent company of the Patheon, DPx Fine Chemicals and Banner Life Sciences businesses. The company offers customers unsurpassed quality, end-to-end solutions and value through its three business units. DPx Holdings is a leading provider of CDMO services, pharmaceutical products and other formulated products for various industries. The company was formed in 2014 as a result of the merger of Patheon and DSM Pharmaceutical Products and is owned by JLL Partners and Royal DSM. With a global headquarters in Durham, N.C., DPx Holdings B.V. has a footprint of more than 20 locations across North America, Europe, Latin America and Australia with approximately 8,800 employees. For more information, visit www.patheon.com/DPx.

      Language:
      English
      Contact:

      DPx Media Relations
      919-210-0986
      media@dpxholdings.com

      ... Read more
    • 29 APRIL 2015

      JLL/Delta Dutch Pledgeco B.V. Announces Offering of $500 Million Senior PIK Toggle Notes due 2020

      Dateline City:
      DURHAM, N.C.

      JLL/Delta Dutch Pledgeco B.V. (the “Company”), the parent company of DPx Holdings B.V., announced today the commencement of a private offering of $500 million aggregate principal amount of its Senior PIK Toggle Notes due 2020 (the “Notes”). The Company intends to use the net proceeds from the offering of the Notes to pay a dividend or other distribution to its parent company and certain related transaction fees and expenses related to the offering.

      The offering of the Notes will be made in a private transaction in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), in the United States only to investors who are “qualified institutional buyers,” as that term is defined in Rule 144A under the Securities Act, or outside the United States pursuant to Regulation S under the Securities Act. The Notes have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.

      This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any of the Notes in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

      Cautionary Statement

      No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

      Forward-Looking Statements

      This press release contains forward-looking statements. These forward-looking statements reflect management’s expectations regarding our future growth, results of operations, operational and financial performance and business prospects and opportunities. All statements, other than statements of historical fact, are forward-looking statements. You can identify such statements because they contain words such as “plans,” “expects” or “does not expect,” “budget,” “forecasts,” “anticipates” or “does not anticipate,” “believes,” “intends” and similar expressions or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved. Although the forward-looking statements contained in this press release reflect management’s current beliefs based upon information currently available to management and upon assumptions which management believes to be reasonable, actual results may differ materially from those stated in or implied by these forward-looking statements.

      About DPx Holdings B.V.

      JLL/Delta Dutch Pledgeco B.V. is the parent company of DPx Holdings B.V., which is the parent company of the Patheon, DPx Fine Chemicals and Banner Life Sciences businesses. The company offers customers unsurpassed quality, end-to-end solutions and value through its three business units. DPx Holdings is a leading provider of CDMO services, pharmaceutical products and other formulated products for various industries. The company was formed in 2014 as a result of the merger of Patheon and DSM Pharmaceutical Products and is owned by JLL Partners and Royal DSM. With a global headquarters in Durham, N.C., DPx Holdings B.V. has a footprint of more than 20 locations across North America, Europe, Latin America and Australia with approximately 8,800 employees. For more information, visit www.patheon.com/DPx.

      Language:
      English
      ... Read more
    • 16 APRIL 2015

      Patheon Scientist to Give Keynote Address at Lyophilisation USA Conference

      Dateline City:
      DURHAM, N.C.

      A top scientific expert at Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will be the keynote speaker at this year's Lyophilisation USA Conference , Wednesday, April 29, through Thursday, April 30, at the Renaissance Woodbridge Hotel in Iselin, N.J.

      Ronald Pate, lyophilization development scientist, will present, "Cycle Development Basic Concepts and Optimizing the Process,” on Wednesday, April 29, at 9:10 a.m. Pate, who has 15 years of freeze drying and lyophilization experience, will highlight how to scale-up and optimize development to enable shorter cycle times and cost efficient processing of lyophilized formulations, while ensuring consistency within batches. He will discuss the science of lyophilization as it relates to freeze drying process control, and the rationale for recommending lyophilzation to clients.

      “I look forward to speaking about lyophilization cycle development,” said Pate. “Lyophilization is often the only way to make a drug substance viable for large scale commercial production. Implicit with the responsibility of developing a safe, effective and efficient lyophilization process, is the reward of knowing that millions of lives will be improved by the quality of your work.”

      For more information and to request a copy of Pate’s presentation, visit http://info.patheon.com/2015-lyophilisation-usa.

      About Patheon

      Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com.

      Language:
      English
      Contact:

      Patheon Media Relations
      +1-919-210-0986
      tyler.gronbach@patheon.com or media@patheon.com

      ... Read more
    • 10 APRIL 2015

      Patheon to Participate in Industry Panels and Feature Patheon OneSourceTM at INTERPHEX

      Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will showcase its broad set of development and manufacturing services, and the company’s integrated offering at INTERPHEX in New York City from Tuesday, April 21, to Thursday, April 23. Company leaders will offer industry insights during key panel discussions sponsored by the Pharma and BioPharma Outsourcing Association.

      Franco Negron, senior vice president of drug product services in North America for Patheon, will participate in the Executive Perspectives panel, moderated by Jim Miller, founder and president of PharmSource Information Services, Inc., Wednesday, April 22 at 1:15 p.m., to discuss industry trends and consolidation, relationships and strategic partnerships with large and small pharma companies, as well as the future of the industry.

      Andrew McNicoll, vice president of quality systems and compliance for Patheon, will participate in a panel focused on Quality Agreements, Wednesday, April 22 at 2:15 p.m. The panel will cover approaches and best practices, and highlight differences in how quality agreements are employed to ensure regulatory compliance when working with clients.

      While at INTERPHEX, Patheon will showcase Patheon OneSourceTM, the industry-leading solution that provides a simplified and customized offering, including both drug substance and drug production services to help clients get to market faster and cost effectively.

      Executives, technical and scientific experts from Patheon will be attending INTERPHEX and will be available to discuss the company’s full suite of services and capabilities at booth #1424. To schedule a meeting in advance, please visit www.patheon.com/Knowledge-Library/Events, and for press inquiries, please email media@patheon.com.

      About Patheon

      Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com .

      Language:
      English
      Contact:

      Patheon Media Relations
      +1-919-210-0986
      tyler.gronbach@patheon.com or media@patheon.com

      ... Read more
    • 1 APRIL 2015

      Patheon Closes Acquisition of IRIX Pharmaceuticals

      Dateline City:
      DURHAM, N.C.

      Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has closed the previously announced transaction to acquire IRIX Pharmaceuticals, a Florence, S.C.-headquartered company that specializes in making difficult to manufacture Active Pharmaceutical Ingredients (API) for drugs from early and late development, through commercial launch. With the acquisition, Patheon establishes a North American presence for comprehensive API development and manufacturing to address customers’ most challenging needs for drugs in all development phases.

      About Patheon

      Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com .

      Language:
      English
      Contact:

      Patheon Media Relations
      919-210-0986
      tyler.gronbach@patheon.com
      media@patheon.com

      ... Read more
    • 20 MARCH 2015

      Patheon Closes Acquisition of Agere Pharmaceuticals

      Dateline City:
      DURHAM, N.C.

      Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has closed the previously announced transaction to acquire Agere Pharmaceuticals, Inc., a privately-held CDMO, that specializes in improving the absorption rate of medications (bioavailability). The company will become part of Patheon’s pharmaceutical development services unit and operate as a solubility center of excellence in Bend, Ore.

      About Patheon

      Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com .

      Language:
      English
      Contact:

      Patheon Media Relations
      919-210-0986
      tyler.gronbach@patheon.com
      media@patheon.com

      ... Read more
    • 12 MARCH 2015

      Patheon Leaders to Attend DCAT Week

      Dateline City:
      DURHAM, N.C.

      Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sector, will participate at DCAT Week 2015 in New York, March 16-19.

      Patheon recently announced two acquisitions in support of the company’s business strategy to enter into logical adjacencies and drive industry consolidation. Patheon offerings now include North American API development and manufacturing services with the addition of IRIX Pharmaceuticals and a solubility center of excellence with the acquisition of Agere Pharmaceuticals.

      As part of DCAT week, Patheon will be honored at the CMO Leadership Awards reception and ceremony hosted by Life Science Leader for the company’s achievements in innovation with emerging pharma. This is the fifth year in a row that Patheon has been recognized for innovation. The CMO Leadership Awards are based on industry research conducted by Nice Insight, a marketing research and intelligence group. The awards recognize companies ranked in the top 10 percent in five perception categories: quality, productivity, reliability, innovation and regulatory by company type.

      DCAT Week is one of the largest gatherings for the pharmaceutical and related industries in the world. Its unique model brings industry CEOs, presidents, global sales managers and directors of supply chain management from around the globe for high-level meetings, strategy sessions, education programs and networking events.

      About Patheon

      Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com .

      Language:
      English
      Contact:

      Patheon Media Relations
      919-210-0986
      tyler.gronbach@patheon.com
      media@patheon.com

      ... Read more
    View More